Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells by Zhang, Baojie et al.
  
 University of Groningen
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Zhang, B., Liu, B., Chen, D., Setroikromo, R., Haisma, H. J., & Quax, W. J. (2019). Histone Deacetylase
Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. Cancers, 11(5), [645].
https://doi.org/10.3390/cancers11050645
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Histone Deacetylase Inhibitors Sensitize
TRAIL-Induced Apoptosis in Colon Cancer Cells
Baojie Zhang, Bin Liu , Deng Chen, Rita Setroikromo, Hidde J. Haisma and Wim J. Quax *
Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of
Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands; b.z.zhang@rug.nl (B.Z.);
bin.liu@rug.nl (B.L.); d.chen.5@student.rug.nl (D.C.); R.Setroikromo@rug.nl (R.S.); h.j.haisma@rug.nl (H.J.H.)
* Correspondence: w.j.quax@rug.nl; Tel.: +31-503-632-558; Fax: +31-503-633-000
Received: 18 April 2019; Accepted: 8 May 2019; Published: 10 May 2019


Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered as a
promising anti-cancer therapeutic. However, many cancers have been found to be or to become
inherently resistant to TRAIL. A combination of epigenetic modifiers, such as histone deacetylase
inhibitors (HDACi’s), with TRAIL was effective to overcome TRAIL resistance in some cancers.
Broad spectrum HDACi’s, however, show considerable toxicity constraining clinical use. Since
overexpression of class I histone deacetylase (HDAC) has been found in colon tumors relative to
normal mucosa, we have focused on small spectrum HDACi’s. We have now tested agonistic
receptor-specific TRAIL variants rhTRAIL 4C7 and DHER in combination with several class I specific
HDACi’s on TRAIL-resistant colon cancer cells DLD-1 and WiDr. Our data show that TRAIL-mediated
apoptosis is largely improved in WiDr cells by pre-incubation with Entinostat-a HDAC1, 2, and 3
inhibitor- and in DLD-1 cells by RGFP966-a HDAC3-specific inhibitor- or PCI34051-a HDAC8-specific
inhibitor. We are the first to report that using RGFP966 or PCI34051 in combination with rhTRAIL 4C7
or DHER represents an effective cancer therapy. The intricate relation of HDACs and TRAIL-induced
apoptosis was confirmed in cells by knockdown of HDAC1, 2, or 3 gene expression, which showed
more early apoptotic cells upon adding rhTRAIL 4C7 or DHER. We observed that RGFP966 and
PCI34051 increased DR4 expression after incubation on DLD-1 cells, while RGFP966 induced more
DR5 expression on WiDr cells, indicating a different role for DR4 or DR5 in these combinations.
At last, we show that combined treatment of RGFP966 with TRAIL variants (rhTRAIL 4C7/DHER)
increases apoptosis on 3D tumor spheroid models.
Keywords: HDAC; TRAIL; RGFP966; PCI34051; DLD-1; WiDr; spheroid; death receptor
1. Introduction
Cancer occurs when cells divide in an uncontrolled fashion and escape the strict mechanisms
of cell death. A promising anti-cancer treatment is to induce apoptosis to prevent malignant cells
from proliferating. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is considered as a
remarkable anti-cancer therapeutic as it has the ability to selectively kill tumor cells, but not normal
cells [1]. Trimeric recombinant human TRAIL can bind to two death receptors, DR4 (TRAIL-R1) and
DR5 (TRAIL-R2) for initiating apoptosis signaling [2,3]. Intracellular death domains in death receptors
interact with Fas-associated death domain (FADD) and pro-caspase 8 or 10, together forming the
death-inducing signaling complex (DISC) [4,5]. This assembly promotes the activation of caspase 8,
which then cleaves the effector caspases, caspase 3 and 7, which ultimately induces DNA fragmentation
and executes apoptosis via the extrinsic pathway [6,7]. Activated caspase-8 can also cleave Bid thereby
generating truncated Bid (tBid), which interacts with Bax and Bak on the mitochondria and promotes
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the release of cytochrome C. This enzyme together with Apaf-1 and caspase 9 forms a functional
apoptosome and results in apoptosis via the intrinsic pathway [8,9].
A recombinant human soluble protein corresponding to 114–281 amino acids of TRAIL has
been developed as a clinical anti-cancer drug Dulanermin. Early clinical Phase I study showed that
Dulanermin was safe in patients with advanced cancer. In addition, peak concentration in serum in a
dose-escalation study was equivalent to those associated with preclinical antitumor efficacy. However,
only 2 patients (3%) with chondrosarcoma had partial treatment responses longer than 6 months [10].
This may be related to resistance to TRAIL, but the resistance mechanism is quite complex and may
involve multiple epigenetic alterations.
With the development of Chromatin Immunoprecipitation Sequencing (ChIP-Seq) it has now been
widely accepted that changes of epigenetic modifications can attribute to tumor progression, drug
resistance, or immune tolerance [11–13]. These changes are independent of DNA sequence alterations
and include at least four modifications of DNA and sixteen classes of histone modifications [14]. One
of the important histone modifications is the histone acetylation, which influences a broad range of
gene activities, such as chromatin condensation, transcription, DNA repair, and DNA replication.
This dynamic process is catalyzed by three groups of enzymes: (1) Histone acetyltransferases (HATs),
also known as ‘writers’, are responsible to transfer acetyl groups to targeted lysine residues in the
amino-terminal tails of core histone proteins; (2) Histone deacetylases (HDACs), known as ‘erasers’,
are found to remove acetyl groups thereby leading to advanced folding of nucleosome to condensed
structures; (3) Bromodomain proteins, known as ‘readers’, specifically recognize acetylated lysine
residues. Aberrant HATs or HDACs activities have been linked to numerous tumors, such as breast,
lung, colorectal, and ovarian cancer. For example, high expression of Class I HDACs has been found
to induce cell proliferation in colon tumors, including HT-29, HCT 116, and SW480 cells [15–17].
Mutations in the HAT genes CREBBP and EP300 were linked to ovarian, breast, colorectal, and lung
tumor types [18,19]. Therefore, inhibition of deacetylation by using HDACi’s seems an attractive
strategy for developing anticancer drugs.
Human HDACs are classified into four classes based on their sequence homology to the yeast
original enzymes: (i) Class I (HDAC1–3 and HDAC8), (ii) Class II (HDAC4–7, HDAC9, and HDAC10),
(iii) Class IV (HDAC11), which are all Zn2+ dependent, and (iv) Class III (SIRT1–7), which are all NAD+
dependent [20,21]. US Food and Drug Administration has already approved several broad spectrum
HDACi’s, including Belinostat (PXD101), Romidepsin (FK228), and Vorinostat (SAHA) for treating
T-cell lymphoma [22–24]. Panobinostat (Farydak) is the first approved HDACi for patients with
multiple myeloma [25]. However, the European Medicines Agency only approved Farydak as other
inhibitors showed rare life-threatening side effects [26]. For example, Panobinostat was found to cause
limited hematologic adverse effects in combination with Lenalidomide/Bortezomib/Dexamethasone
in Phase I/II trials [27]. However, SAHA was reported to induce pulmonary embolism, deep vein
thrombosis, and hyper glycaemia. PXD101 and FK228 cause infections and tumor lysis syndrome [28].
These safety concerns led to great efforts from researchers aiming at development of specific
HDACi’s. Currently, a number of HDAC-selective inhibitors are under investigation for use in
oncology, including (1) RGFP966, a HDAC3-specific inhibitor, decreases the growth of prostate cancer
models [29]; (2) PCI34051, a HDAC8-specific inhibitor, induces apoptosis of T-cell malignancies [30];
and (3) Tubacin, a HDAC6-specific inhibitor, suppresses proliferation of acute lymphoblastic leukemia
cells [31]. The mentioned selective HDACi’s are supposed to give lower toxicity than pan-HDACi’s.
Therefore, they seem appropriate to be used in combination therapies aimed at improving antitumor
effects synergistically. Hence, we chose RGFP966 or PCI34051 to be used in combination with
apoptosis-inducing ligands in colon cancer. Both rhTRAIL 4C7 and DHER have shown superior
apoptosis-inducing effects in colon tumor cells compared to rhTRAIL, but a number of cell lines to a
lesser (DLD-1) or higher (WiDr) extend show resistance [32,33].
Here, we investigated the role of individual HDAC1, 2, and 3 in colon cancer cells DLD-1 and
WiDr using different HDACi’s with partially overlapping specificities. Additionally, we combined
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these inhibitors with two TRAIL variants, DR4-specific rhTRAIL 4C7 and DR5-specific rhTRAIL DHER,
to further unravel the antitumor effects. Our results show that RGFP966 improves TRAIL-induced
apoptosis via both DR4 and DR5 receptors and its antitumor effect in combination with rhTRAIL 4C7
or DHER is close to the effect by SAHA combined with TRAIL variants. PCI34051 also enhances cell
death in combination with rhTRAIL variants. Moreover, the same trend can be found on HDAC1,
2, 3, or 8 knocked down cell lines. Finally, we measured the antitumor effect in 3D spheroid culture
mimicking in vivo models. In trying to understand mechanism, we monitored the surface expression
of DR4 and DR5 and we analyzed cell cycle changes in HDACi’s-treated cells.
2. Results
2.1. HDACi’s Enhance Cell Death in Combination with Receptor-Specific TRAIL Variants rhTRAIL 4C7
and DHER
It has been found that HDAC1, 2, 3, and 8 are overexpressed in colon tumor cells, but the function
of individual HDAC in cancer metabolism is still unclear. To study the role of the respective HDACs
we performed cell viability assays testing the sensitivities of DLD-1 and WiDr cells to various HDACi’s.
Additionally, we used DR4-specific TRAIL variant 4C7 and DR5-specific TRAIL variant DHER to study
apoptosis via DR4 and DR5 separately. Here, we observed that single treatment of SAHA already
induces a relatively high cell death (Figure 1A,B). To focus on Class I HDACs, we chose (i) Entinostat,
a HDAC1, 2, 3 selective inhibitor; (ii) RGFP966, a HDAC3-specific inhibitor; and (iii) PCI34051, a
HDAC8-specific inhibitor. Figure 1A shows that at 10 µM Entinostat on its own induces around 70%
cell death whereas RGFP966 or PCI34051 does not cause cell death. However, RGFP966 significantly
increases cell death in the presence of either rhTRAIL 4C7 or DHER in DLD-1 cells indicating that
HDAC3 may play an important role in stimulating TRAIL-induced cell death. Additionally, we detected
additive cell death caused by PCI34051+rhTRAIL 4C7 or DHER in DLD-1 cells, which indicates that
PCI34051 may trigger cell death dependent of TRAIL-induced pathways. Since DLD-1 cells are sensitive
to rhTRAIL 4C7, the absolute increase in dead cells caused by rhTRAIL 4C7+RGFP966/PCI34051 is
less pronounced than by rhTRAIL DHER+RGFP966/PCI34051 (Figure 1A). Interestingly, in WiDr cells
rhTRAIL DHER+RGFP966 induces more cell death than rhTRAIL 4C7+RGFP966 (Figure 1B). This
implies that DR5 may be more active than DR4 in TRAIL-mediated apoptotic signaling treated by
the combination. A relative higher increase of cell death was detected at a low concentration (5 µM)
of HDACi’s (Figure S1). Notably, we are the first to show that RGFP966/PCI34051 enhances TRAIL
sensitivity in colon cancer cells. The DLD-1 cell death caused by RGFP966+rhTRAIL 4C7 is quite
comparable to the one caused by SAHA/Entinostat+rhTRAIL 4C7 treatment, which implies a crucial
role for HDAC3 in enhancing TRAIL-mediated cell death.
2.2. RGFP966 and PCI34051 Improve TRAIL-Induced Apoptosis
In order to further investigate the mode of action of the combination treatment of HDACi and
rhTRAIL variants on colon cancer cells, we examined apoptotic cells using the Violet Ratiometric
Membrane Asymmetry Probe. Figure 2A shows that incubation by 5 µM SAHA or Entinostat on DLD-1
already induced early and late apoptosis whereas a combination treatment with rhTRAIL 4C7 or DHER
further increased apoptosis. This additional effect was less pronounced using rhTRAIL 4C7 than DHER,
which is due to the already high sensitivity of DLD-1 cells to rhTRAIL 4C7. Different from DLD-1 cells,
WiDr cells are resistant to both rhTRAIL 4C7 and DHER (Figure 2B). Entinostat in combination with
any of the TRAIL variants significantly enhances cell apoptosis in WiDr cells. In line with the cell
viability study, 5 or 10 µM RGFP966 or PCI34051 in combination with rhTRAIL 4C7 or DHER largely
increases apoptosis in DLD-1 and WiDr cells (Figure 2A and Figure S2B). Additionally, microscopic
examination of DLD-1 cells (Figure 2C) or WiDr cells (Figure S2A), reveals that cells detach, lose
confluent growth, and start floating in the medium, which is triggered by the combination treatment.
Furthermore, caspase-3/7 activity was found to be increased by combination treatment on DLD-1 cells
indicating that caspase-dependent apoptosis is transmitted downstream pathways (Figure 2D,E). In
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conclusion, these results confirm that RGFP966 and PCI34051 sensitize TRAIL-induced apoptosis via
DR4 and DR5 on DLD-1 cells, while this increased apoptosis is less pronounced on TRAIL-resistant
WiDr cells. However, Entinostat significantly increased DR4 and DR5-mediated apoptosis on WiDr
cells, indicating that HDAC1 and HDAC2 may be crucial for sensitizing TRAIL-resistant cells to TRAIL.
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Figure 1. Alterations of cell viability after treatment with HDAC inhibitors and rhTRAIL variants 4C7 
or DHER. DLD-1 cells (A) or WiDr cells (B) were firstly treated with 10 μM HDAC inhibitors 
including SAHA, Entinostat, RGFP966, or PCI34051, respectively, for 24 h and the day after cells were 
incubated with rhTRAIL 4C7 or DHER overnight. Cell viability was determined by MTS assay. The 
values shown are mean ± SD from one of three experiments performed in triplicate. p values were 
analyzed by one-way ANOVA in Turkey’s multiple comparison with Graphpad Prism version 7.0.  
** 0.001 ≤ p ≤ 0.01, **** p ≤ 0.0001. 
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analyzed by one-way ANOVA in Turkey’s multiple comparison with Graphpad Prism version 7.0. *
0.01 ≤ p ≤ 0.05, ** 0.001 ≤ p ≤ 0.01.
2.3. Knockdown of HDAC1, 2, 3, 8 Enhances TRAIL Sensitivity
The above results indicate that inhibition of HDAC1, 2, 3, and 8 increases the sensitivity to
TRAIL-induced apoptosis. Therefore, we next focus on silencing HDAC1, 2, 3, and 8 individually
and investigating the alterations of colon cancer cells (DLD-1 and WiDr) in response to DR4 and
DR5-induced apoptosis. Cells were transduced either with scrambled siRNAs or a pool of HDAC1, 2,
3, or 8 siRNAs. qRT-PCR shows a clear decrease in expression of HDAC1, 2, 3, and 8 at mRNA level
with knockdown levels in DLD-1 being better than in WiDr (Figure 3A,B). Apoptotic cells induced
by knockdown of HDAC genes alone or in combination with rhTRAIL 4C7 or DHER treatment were
investigated. It can be seen that downregulating the expression of HDAC1, 2, or 3 on DLD-1 (Figure 3C)
induces early and late apoptosis, while HDAC 8 does not. This implies that HDAC1, 2, and 3 are
connected with cell apoptosis and therefore may crosstalk with a TRAIL-mediated apoptosis pathway.
Interestingly, early apoptotic cells increased after adding rhTRAIL 4C7 or DHER on HDAC knockdown
cells in comparison with scramble control as shown in Figure 3D,E, which indicates that both DR4 and
DR5 are involved in the signaling pathway. Notably, the amount of apoptotic cells induced by rhTRAIL
variants in HDAC3 or 8 knockdown DLD-1 cells are almost the same as in HDAC1 or 2 knockdown
cells. In WiDr cells, downregulation of HDAC1 or 2 induces apoptosis, while HDAC3 or 8 not, which
is in line with the observed low toxicity of HDAC3- and 8-specific inhibitors (Figure 3E and Figure S3).
Moreover, percentages of apoptotic cells induced by rhTRAIL variants in HDAC3 or 8 knockdown
WiDr cells are lower than that in HDAC1 or 2 knockdown cells, implying an important role of HDAC1
or 2 in connection to TRAIL-mediated apoptosis.
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Lipofectamine 2000. Relative mRNA levels were normalized by α-tubulin. The values shown are mean 
± SD from one of three experiments performed in triplicate. (C) After 72 h transfection, DLD-1 cells 
were treated with 25 ng/mL rhTRAIL 4C7 or DHER and apoptotic cells were detected using the Violet 
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left group represents early apoptotic cells, and the upper left group represents late apoptotic or dead 
cells. Statistical analysis of DLD-1 (D) or WiDr (E) cells was shown. 
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Figure 3. Knockdown of HDAC1, 2, 3, or 8 enhances TRAIL sensitivity. DLD-1 (A) or WiDr (B) cells were
transfected with siRNAs of scramble or HDAC1, 2, 3, and 8 respectively for 72 h using Lipofectamine
2000. Relative mRNA levels were normalized by α-tubulin. The values shown are mean ± SD from
one of three experiments performed in triplicate. (C) After 72 h transfection, DLD-1 cells were treated
with 25 ng/mL rhTRAIL 4C7 or DHER and apoptotic cells were detected using the Violet Ratiometric
Membrane Asymmetry Probe. The lower right group represents living cells, the lower left group
represents early apoptotic cells, and the upper left group represents late apoptotic or dead cells.
Statistical analysis of DLD-1 (D) or WiDr (E) cells was shown.
2.4. RGFP966 or PCI34051 Improves TRAIL-Induced Apoptosis in 3D Spheroid Model
As we concluded above, RGFP966 and PCI34051 are promising drugs in combination with rhTRAIL
4C7 or DHER to improve apoptosis in colon cancer cells. To mimic actual tumor microenvironment
and further demonstrate feasibility of our study, we investigated this combination on 3D spheroids
which are considered as more valid models to recapitulate features of tumor micro metastases as they
have a specific architecture that 2D monolayer culture cannot produce. We firstly established 3D
spheroids by culturing DLD-1 and WiDr cells in ultra-low attachment plates (Figure 4A). Spheroids
were subsequently treated with RGFP966 or PCI34051+rhTRAIL 4C7 or DHER followed by caspase 3/7
activity assay. Active caspa e-3/7 largely increased after adding rhTRAIL 4C7 or DHER in comparison
with only RGFP966 incubation. Additionally, activity of caspase-3/7 also improved afte incub ting
with rhTRAIL 4C7 and PCI34051, while no obvious activity increase was detected after incubating
with rhTRAIL DHER and PCI34051.
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plates. Morphology changes were observed under an inverted light microscope with 40× agnification.
(B) The DLD-1 spher ids were generated and transferr d to a 96-well white wall plate and caspase3/7
activity was detected after adding 5 ng/mL rhTRAIL 4C7 or DHER overnight. Luminescence were
measured after 2 h incubation with caspase 3/7 reagent. p values were nalyzed by one-way ANOVA
in Turkey’s multiple comparison with Graphpad Prism version 7.0. * 0.01 ≤ p ≤ 0.05, ** 0.001 ≤ p ≤ 0.01.
2.5. Expressions of Death Receptors and Cell Cycle Alter Upon HDACi’s Treatment
It has been di covered th t SAHA induces overexpression of DR5 on the hep ocellular carcinoma
cell membrane leading to improvement of TRAIL sensitivity [34]. However, whether this mechanism
happens in colon cancer cells is still unclear. To further study the mechanism, we investigated the
expression of both DR4 and DR5 after incubation for 48 h with different concentration of RGFP966
or PCI34051 in a 2D culture. Surprisingly, we detected a 1.5-fold increase of DR4 but not DR5 after
incubating with RGFP966 for 48 h and a 2-fold increase of DR4 after incubating with PCI34051 on
DLD-1 cells (Figure 5A and Figure S4A). Interestingly, DR5 expression increased after incubating
with RGFP966 on WiDr cells for 48 h (Figure 5B and Figure S4B). These changes of death receptor
expression may lead to a different sensitivity to TRAIL-mediated apoptosis. In addition, we also
studied alterations of the cell cycle with treatment of HDACi’s as apoptosis is related to cell cycle
arrest [35]. Figure 6A,C showed that PCI34051 arrests G0/G1 phase after incubating 24 h, while
RGFP966 does not change the cell cycle in DLD-1 cell line. Either RGFP966 or PCI34051 changes the
cell cycle in WiDr cell line (Figure 6B,D). It has been reported that SAHA and Entinostat induced cell
cycle arrest. We also observed G2 phase arrest after incubating with SAHA for 24 h and G0/G1 phase
arrest after incubating with Entinostat for 24 h in DLD-1 and WiDr cells (Figure S5). Alterations of the
cell cycle may contribute to the mechanism of increasing TRAIL sensitivity as well.
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were measured after incubation. Statistical analysis in (C) or (D) are according to (A) or (B). The values
shown are mean ± SD from one of three experiments performed in triplicate. p values were analyzed by
one-way ANOVA in Turkey’s multiple comparison with Graphpad Prism version 7.0. * 0.01 ≤ p ≤ 0.05.
3. Discussion
Administration of TRAIL has been considered as a promising antitumor therapy for a long time
due to its tumor selective properties. However, studies have how that approximately 50% of the
colorectal cancer cel s are resistant to TRAIL [36 37], se mingly due to v rious genetic and epigenetic
m difications in the signaling pathway. Combination therapies aimed at elieving this resistanc have
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recently been investigated. In clinical studies, combinations of Dulanermin with FOLFIRI regimen
(with or without Bevacizumab)/Cetuximab/Irinotecan have already been tested but without the desired
result (NCT00671372, NCT00873756) implying that is still a need for a good combination drug for
Dulanermin. Here, we for the first time evidence that combining RGFP966 or PCI34051 with our
mutants rhTRAIL 4C7 or DHER significantly improves apoptosis induction [32,33].
Many studies have discussed the complexity of the mechanism of TRAIL resistance and one
of elements is epigenetic regulation such as histone acetylation [38,39]. In previous studies, TRAIL
has been combined with SAHA in hepatocellular carcinoma, non-small cell lung cancer, or breast
cancer and this showed a large improvement in apoptosis indicating the potential role of epigenetic
modification [34,40,41]. Since SAHA as a broad-spectrum inhibitor has many side effects for clinical use,
we tested different small spectrum HDACi’s for their potential to enhance TRAIL mediated apoptosis
in two colon cancer cells DLD-1 and WiDr. Notably, our MTS results show that HDAC3-specific
inhibitor RGFP966 and HDAC8-specific inhibitor PCI34051 both increase cell death of DLD-1 and
WiDr after treatment with rhTRAIL 4C7 or DHER. Further investigations of cell apoptosis suggest that
inhibition of HDAC3 or 8 facilitate rhTRAIL 4C7- or DHER-induced apoptosis.
We next generated HDAC1, 2, 3, and 8 knockdown cells for more precise mechanism study. Studies
have shown roles of HDAC3 or HDAC8 in colon cancer cells. Spurling et al. reported that HDAC3 is
overexpressed in SW480 cells resulting in proliferation and differentiation [16]. Kang et al. recently
found that HDAC8 is associated to activator of transcription 3 (STAT3)/specificity transcription 3 (Sp3)
exchange and induces Bmf-dependent apoptosis [32]. DLD-1 and WiDr cells response differently on
the administration of HDAC inhibition, which may be related to the differences in epigenetic and
genetic background of these two cell lines. It has been reported that DLD-1 cells contain a KRAS
mutation while WiDr does not [42,43]. This mutation may be connected to hyperactivation of DNA
methylation in these colon cancer cells since upregulation of DNA methylation was discovered after
transformation of fibroblasts by ras oncogene [16]. Increasing DNA methylation may lead to recruitment
of HDAC explaining a more pronounced effect of HDACi’s in DLD-1 cells [44]. Three-dimensional
spheroid models have been developed to mimic actual tumor microenvironment in the body. Here,
we generated 3D spheroids and showed increased apoptosis induced by RGFP966 in combination
with rhTRAIL 4C7 or DHER. There are some studies show that TRAIL-induced apoptosis is regulated
by post-translational modifications of death receptors [45]. O-glycosylation of DR4 and DR5 was
proven to control the sensitivity of many cancer cells to TRAIL [36]. Subsequently, Dufour et al.
reported that N-glycosylated DR4 promotes TRAIL signaling [46]. Moreover, we previously found
that DR5 is activated by fucosylation for TRAIL-induced apoptosis using our TRAIL variants [47].
Interestingly, recently a relation between HDAC inhibition and glycosylation pattern was reported
which can hint at an explanation for increasing sensitivity of TRAIL receptors in the presence of
HDAC inhibitors [48]. In our current study, we investigated the expression of DR4 and DR5 on the
cell membrane and our results show significant DR4 but not DR5 expression enhancement on DLD-1
cells, while DR5 but not DR4 expression is increased on WiDr cells. It is of interest to further explore
precise mechanisms of alterations of DR4 and DR5 expression induced by HDACi’s using ChIP-Seq.
Interestingly, a study showed that G1 cell cycle arrest in melanoma cells is strongly correlated with
enhanced TRAIL-mediated apoptosis [35]. We observed G0/G1 arrest upon the treatment of PCI34051
indicating that a similar mechanism occurs in colon cancer cells. Taken together, our findings give a
new insight into the effect of HDACs on TRAIL-mediated apoptosis and they imply a promising novel
antitumor therapy using TRAIL variants with HDAC3-specific inhibitor RGFP966 or HDAC8-specific
inhibitor PCI34051.
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4. Materials and Methods
4.1. Cell Lines and Culture Conditions
Human colon cancer cells of DLD-1 and WiDr were obtained from American Type Culture
Collection (ATCC, Wesel, Germany) and cultured in RPMI1640 medium supplemented with 10% fetal
bovine serum (FBS), 100 units/mL Penicillin, and 100 µg/mL Streptomycin in a humidified incubator
at 37 ◦C with 5% carbon dioxide. Basal medium RPMI1640, FBS, Penicillin, and Streptomycin were
purchased from Thermo Fisher Scientific (Waltham, MA, USA).
4.2. Cell Viability Assay
DR4-specific TRAIL variant rhTRAIL 4C7 and DR5-specific TRAIL variant rhTRAIL DHER (amino
acids 114–281) were constructed and produced as previously described [32,33]. Cells were seeded
in triplicate in 96-well plates at a concentration of 30,000 cells/mL in 100 µL complete medium and
maintained overnight prior to the treatment. Cells were treated with 5 µM or 10 µM HDACi’s including
SAHA, Entinostat, RGFP966, and PCI34051 overnight and 0–50 ng/mL rhTRAIL 4C7 or DHER were
added at the following day. After overnight incubation, cells were incubated with 20µL/well MTS
reagent (Promega, Madison, WI, USA) for 1.5 h according to the manufacturer’s instruction. Cell
viability was determined by measuring the absorbance at 490 nm using a microplate reader (BMG
LABTECH, De Meern, Utrecht, The Netherlands). All HDACi’s were purchased from Selleckchem
(Munich, Germany).
4.3. Apoptotic Assay
The 2 × 105 cells were seeded in 3 mL complete medium in 6-well plates 24 h prior to the
treatment. The next day, cells were treated with 10 µM HDACi’s at a final volume of 1 ml overnight.
25 ng/mL rhTRAIL 4C7 or DHER were added at the following day and incubated overnight. After
treatment, cells were collected and washed with PBS twice. Cell pellets were resuspended in 200 µL
PBS containing reagent A and B from cell apoptotic kit (Violet Ratiometric Membrane Asymmetry
Probe/Dead cell Apoptotic Kit) bought from Thermofisher Scientific (Waltham, MA, USA). Cells were
measured and analyzed by LSR-II (BD Bioscience, Franklin Lakes, NJ, USA). Imagines were taken
under the microscope after treatment at different time points. For HDAC knockdown cells, rhTRAIL
4C7 or DHER were added after 72 h transfection.
4.4. Caspase 3/7 Activity Assay
Cells were seeded in triplicated in a 96-well plate with white walls at a density of 30,000 cells/mL
overnight before the treatment. Cells were pre-incubated for 24 h with 10 µM HDACi’s and followed by
the treatment with 25 ng/mL rhTRAIL 4C7 or DHER. The next day 100 µL reagent was added according
to the manufacturer’s protocol and incubated for 2 h at room temperature (Promega, Madison, WI,
USA). Luminescent was measured with a Synergy™ H1 plate reader (BioTek, Winooski, VT, USA).
For the 3D spheroids, every spheroid was transferred to 96-well plate with white walls before adding
reagent. Reagent were incubated for 2 h at room temperature with spheroid and the same measurement
as monolayer cells was conducted.
4.5. HDAC1, 2, 3, and 8 Knockdown Using siRNA
Cells were seeded at 2 × 105 per well in 6-well plates and incubated for 24 h. The next day cells
were transfected with predesigned pool of small interfering RNA (siRNA) oligonucleotides at a final
concentration of 600 ng/mL (HDAC1 and 2) or 5 nmol/L (HDAC3 and 8) with Lipofectamine 2000
Reagent (Thermo Fisher Scientific, Waltham, MA, USA). After 72 h incubation, cells were collected
for qRT-PCR. siRNA of HDAC1 (MISSION, esiRNA HDAC1) and 2 (MISSION, esiRNA HDAC2)
were purchased from Millipore Sigma (Burlington, MA, USA). siRNA of HDAC3 (M-003496-02-0005,
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siGENOME Human HDAC3 (8841) siRNA-SMART pool) and 8 (M-003500-02-0005, siGENOME Human
HDAC8 (55869)-SMART pool) were purchased from GE Healthcare Dharmacon (Lafayette, LA, USA).
4.6. 3D Spheroid Construction
1000 cells per well were seeded in ultra-low attachment plates with 96-wells (Corning Incorporated,
Kennebunk, ME, USA). Plates were centrifuged at 1000 rpm for 5 min to initiate the formation of 3D
spheroid. After 3 days incubation, spheroids were generated and ready for performing experiments.
4.7. RNA Isolation and Quantitative Reverse Transcriptase PCR (qRT-PCR)
Cells were washed by PBS and harvested by trypsin. RNA was isolated using Maxwell LEV
simply RNA Cells/Tissue Kit (Promega, Madison, WI, USA) and then concentrations of RNA was
measured by NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was synthesized from
200 ng RNA using Reverse Transcription Kit (Promega, Madison, WI, USA) according to instruction
of manufacture. The 20 ng cDNA and SensiMix SYBRkit (Bioline, Taunton, MA, USA) were used
to perform qRT-PCR in an ABI Prism 7900HT Sequence Detection System (Thermo Fisher Scientific,
Waltham, MA, USA). Primers sets are listed in Table S1. Data was analyzed by SDS v.2.3 software
(Applied Biosystems, Foster City, CA, USA). mRNA level of α-tublin was measured and used as a
reference for data normalization.
4.8. Death Receptor Expression Analysis
Cells were seeded at 2 × 105 per well in 6-well plate overnight. The next day, 5 µM or 10 µM
HDACi’s were added and incubated for 24 h or 48 h. After incubation, cells were collected and
washed with FACS buffer (PBS with 1% FBS). Then cells were incubated with primary antibodies
for DR4 (abcam, Cambridge, UK) or DR5 (EXBIO Praha, Nad Safinou, Czech Republic) on ice for
1 h. Subsequently, cells were washed and incubated with R-Rhycoerythrin (PE) conjugated goat
anti-rabbit antibody (Southern Biotech, Birmingham, AL, USA) or Fluorescein (FITC) conjugated
donkey anti-mouse antibody (Jackson ImmunoResearch Europe, Cambridge, UK) on ice for 1 h. DR4
and DR5 expression was detected using a FACS Calibur flow cytometer (BD Bioscience, Franklin Lakes,
NJ, USA).
4.9. Cell Cycle Analysis
Cells were seeded at 2 × 105 per well in 6-well plate overnight. The following day cells were
treated with 5 µM HDACi’s for 24 h or 48 h. After incubation cells were harvested by PBS and trypsin.
Cell pellets were washed and cells were fixed using cold 70% ethanol overnight at 4 degree. At last,
cells were harvested and DNA was stained with 20 ug/mL propidium iodide (Thermo Fisher Scientific,
Waltham, MA, USA). Cell cycle were detected using a FACS Calibur flow cytometer (BD Bioscience,
Franklin Lakes, NJ, USA).
4.10. Data Analysis
Data were presented as mean± SD from one of three experiments performed in triplicates. p values
were analyzed by one-way ANOVA in Turkey’s multiple comparison with Graphpad Prism version
7.0 (San Diego, CA, USA). ** p ≤ 0.005, *** p ≤ 0.0005, **** p ≤ 0.0001. Cell apoptosis and death receptor
expression were analyzed by FlowJo V10 (BD Bioscience, Franklin Lakes, NJ, USA). Cell cycle was
analyzed by ModFit LT (Verity Software House, Topsham, ME, USA).
5. Conclusions
Our data show that both HDAC3 inhibitor (RGFP966) and HDAC8 inhibitor (PCI34051) sensitize
to TRAIL-mediated apoptosis most likely through changes in death receptor expression and cell cycle
arrest. This represents a novel effective combination therapy to kill colon cancer cells.
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to rhTRAIL 4C7 or DHER, Figure S2: HDAC inhibitors increase TRAIL-mediated apoptosis, Figure S3: After 72
h transfection with siRNA, WiDr cells were treated with 25 ng/mL rhTRAIL 4C7 or DHER and apoptotic cells
were detected using the Violet Ratiometric Membrane Asymmetry Probe, Figure S4: Alterations of death receptor
expression after incubating with 10 µM RGFP966 or PCI34051 for 24 h or 48 h on DLD-1 (A) or WiDr (B) cells,
Figure S5: SAHA or Entinostat changes cell cycle after incubating for 24 h on DLD-1 (A) or WiDr (B) cells. Red
peaks represent G0/G1 and G2 phase, Table S1: List of primer sets used for qRT-PCR.
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